Our Experts

At NDA we’re a team of experts – experts in the regulated disciplines, and experts in drug development.

Some of us have attained our experience from working inside regulatory authorities, carefully assessing the benefits and risks of new treatments. Some of us have worked for years in the biotech and pharmaceutical industry, patiently developing life changing products for patients suffering from debilitating and sometimes deadly diseases and conditions.

Whatever our background, we share a passion for the art and science of drug development and for making a difference to the clients and the patients we ultimately serve.

Get to know the people behind the passion – read more about our incredible team below.

01-10-2020

Dr Olivier Wong

Advisory Board Member
Expert in study design from an HTA and payer perspective
01-10-2020

Dr Thomas Lönngren

Strategic Advisor
Expert in the EU regulatory system and global regulatory strategies
01-10-2020

Graham Higson

Advisory Board Member
Expert in global regulatory strategy and drug development
02-10-2020

Professor Félix Lobo

Advisory Board Member
Expert in health economics and the pharmaceutical industry
01-10-2020

Professor J.-Matthias Graf von der Schulenburg

Advisory Board Member
Expert in pricing and reimbursement with a special focus on Germany
01-10-2020

Professor Martin Buxton

Advisory Board Member
Expert in economic evaluation and appraisal of health technologies
01-10-2020

Professor Mira Pavlovic-Ganascia, MD

Advisory Board Member
Expert in joint regulatory, early dialogue, and HTA advice
01-10-2020

Professor Peter Kolominsky-Rabas

Advisory Board Member
Expert in HTA, market access, and real-world evidence

Contact Us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World